Skip to main content

Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026

Written by Customer Service on . Posted in Public Companies.

SHANGHAI, Sept. 03, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, announced today that its “AI + Chronic Care” platform has been named to the 2026 Fortune China Best Designs list, recognizing the Company’s innovation and application of artificial intelligence in chronic disease management.

Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026

Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026

Now in its fifth year, Fortune China’s Best Designs list evaluates projects across innovation, real-world implementation, industry value, and broader social impact. The 2026 list places a particular focus on artificial intelligence, recognizing projects that apply innovation to address industry challenges while demonstrating commercial potential and social value. Fangzhou’s inclusion highlights the practicality, scalability, and commercial viability of its AI-powered chronic care model.

Chronic disease management remains a critical pillar of China’s public healthcare system, yet traditional models face persistent challenges, including fragmented services, high labor costs, inconsistent patient follow-ups, and limited personalization. To address these structural constraints and long-term care needs, Fangzhou began exploring AI applications in healthcare as early as 2022.

In 2025, powered by its proprietary “XingShi” Large Language Model (XS LLM), the Company launched its “AI + Chronic Care” service model. By embedding AI functionality across the entire patient journey—including health monitoring, medication guidance, follow-up management, and health education—the platform connects fragmented services into a more seamless and personalized care experience.

As the Company scaled its deployment of XS LLM in 2026, the model delivered tangible benefits across both patient and physician workflows:

  • Workflow Optimization: Streamlines service delivery across both physician and patient touchpoints by automating routine tasks and processes to enhance operational efficiency
  • Enhanced Care Quality & Patient Adherence: Integrates professional clinical guidance into everyday health management, empowering individuals to build healthier routines and manage chronic conditions more effectively

This recognition from Fortune China marks another milestone in Fangzhou’s strategic evolution into a “full-lifecycle personal health service partner.” Looking ahead, the Company will continue to integrate AI technology across broader healthcare scenarios, advancing the scaled deployment of new capabilities to drive industry-wide efficiency and support the long-term development of digital healthcare.

About Fangzhou Inc.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 59.8 million registered users and 282,000 physicians (as of June 30, 2026). The Company specializes in delivering tailored medical care and AI‑enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact

For further inquiries or interview requests, please contact:

Xingwei Zhao
Director of Public Relations
Email: pr@jianke.com

Disclaimer: This press release contains forward‑looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1b0248-d3d5-4e19-af29-3077d7a24ad0

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.